Financials Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret
Equities
ANGEN
TREANGN00028
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.18 TRY | +0.53% | -7.51% | +5.86% |
Valuation
Fiscal Period: December | 2021 | 2022 |
---|---|---|
Capitalization 1 | 3,212 | 4,741 |
Enterprise Value (EV) 1 | 2,701 | 4,330 |
P/E ratio | 5.1 x | 14.3 x |
Yield | - | 2.76% |
Capitalization / Revenue | 7.83 x | 17.6 x |
EV / Revenue | 6.59 x | 16.1 x |
EV / EBITDA | 8.48 x | 27.5 x |
EV / FCF | 35,680,324 x | -439,718,036 x |
FCF Yield | 0% | -0% |
Price to Book | 4.19 x | 5.81 x |
Nbr of stocks (in thousands) | 220,000 | 220,000 |
Reference price 2 | 14.60 | 21.55 |
Announcement Date | 3/3/22 | 3/10/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 |
---|---|---|---|
Net sales 1 | 421.6 | 410.1 | 268.8 |
EBITDA 1 | 347.3 | 318.7 | 157.3 |
EBIT 1 | 342.3 | 308.9 | 136.4 |
Operating Margin | 81.2% | 75.33% | 50.73% |
Earnings before Tax (EBT) 1 | 359.7 | 462.3 | 340.3 |
Net income 1 | 293.4 | 433.3 | 330.4 |
Net margin | 69.6% | 105.66% | 122.9% |
EPS 2 | 1.938 | 2.862 | 1.502 |
Free Cash Flow | - | 75.71 | -9.847 |
FCF margin | - | 18.46% | -3.66% |
FCF Conversion (EBITDA) | - | 23.76% | - |
FCF Conversion (Net income) | - | 17.47% | - |
Dividend per Share | - | - | 0.5958 |
Announcement Date | 3/3/22 | 3/3/22 | 3/10/23 |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 |
---|---|---|---|
Net Debt 1 | - | - | - |
Net Cash position 1 | 105 | 511 | 411 |
Leverage (Debt/EBITDA) | - | - | - |
Free Cash Flow | - | 75.7 | -9.85 |
ROE (net income / shareholders' equity) | - | 76.3% | 40.9% |
ROA (Net income/ Total Assets) | - | 30.8% | 9.93% |
Assets 1 | - | 1,409 | 3,327 |
Book Value Per Share 2 | 2.050 | 3.490 | 3.710 |
Cash Flow per Share 2 | 0.8900 | 2.100 | 1.470 |
Capex 1 | 69.6 | 77.4 | 94.1 |
Capex / Sales | 16.51% | 18.88% | 35.01% |
Announcement Date | 3/3/22 | 3/3/22 | 3/10/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+5.86% | 89.39M | |
+29.08% | 49.18B | |
+0.93% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.29% | 26.09B | |
-22.68% | 18.71B | |
+8.09% | 13.26B | |
+32.15% | 12.32B | |
-0.52% | 11.99B |
- Stock Market
- Equities
- ANGEN Stock
- Financials Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret